Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

DK: New agreement to supply MMJ products for Denmark

Emerald Health Therapeutics has signed an agreement to become a new supplier to Stenocare A/S of medical cannabis for Denmark and Stenocare's international markets.

"Since early September 2019, Emerald and Stenocare have worked closely together to pre-qualify Emerald’s products and production methods," the team with the company explain. "Stenocare and Emerald will now commence the work with the Danish Medicines Agency to have Emerald’s products ready and approved for the Danish Medical Cannabis Pilot Programme. The companies are aiming for product approval for CBD oil, THC oil and CBD+THC oil. The partnership is also intended to extend to Stenocare’s Irish subsidiary and to additional markets which are being evaluated."

“Stenocare has carefully evaluated potential new suppliers of medical cannabis in order to supply products suitable for Danish patients according to the strict requirements of the Danish Medicines Agency. We selected Emerald because of their strong capabilities across cultivation, processing, formulation and testing,” said Thomas Skovlund Schnegelsberg, CEO of Stenocare. “We have previously been supplying medical cannabis to hospitals and pharmacies and have a ready customer base awaiting a new supply of products. We expect our partnership with Emerald to help us meet this demand and support Stenocare's vision of supplying medical cannabis that helps patients to achieve a better quality of life.”

“We respect Stenocare professionalism and their accomplishment in establishing leading distribution channels for medical cannabis in Denmark. We also appreciate their trust in Emerald’s capabilities and standards as they transition to new preferred supplier relationships,” said Riaz Bandali, CEO of Emerald. “As Emerald ramps up production at its two recently fully-licensed production facilities, we look forward to fulfilling our commitment to Stenocare and helping them to serve Danish patients.”

On January 1st, 2018, medical cannabis was legalized in Denmark under a four-year trial-programme, enabling all Danish physicians to prescribe cannabis for medical use. This programme also allows vendors that have been licensed by the Danish Medicines Agency (DMA) to cultivate, produce, import and distribute medical cannabis.

For more information:
STENOCARE A/S 
Frederiksborgvej 54 3450 Allerød Danmark 
+45 253 266 56 
info@stenocare.com  
stenocare.dk      

Emerald Health Therapeutics
emeraldhealth.ca 

Publication date: